Peptide inhibitors of HIV-1 egress.
HIV-1 release requires a direct interaction between the p6 domain of the Gag protein and Tsg101, a component of the cellular endosomal sorting complex required for transport I (ESCRT-I). Disruption of the binding between Gag and Tsg101 is highly detrimental to particle release, making this viral-host cell interaction a potential target for the development of novel anti-HIV-1 agents. An article in this issue reports on the application of a bacterial reverse two-hybrid strategy to identify a cyclic peptide that disrupts Gag-Tsg101 binding and suppresses HIV-1 particle release.
Waheed
Abdul A
AA
Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland 21702, USA.
Freed
Eric O
EO
D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D056827:Endosomal Sorting Complexes Required for Transport; D011992:Endosomes / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D008954:Models, Biological; D010456:Peptides, Cyclic / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D014157:Transcription Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D033921:Vesicular Transport Proteins / Q000187:drug effects / Q000378:metabolism; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000099177:Tsg101 Protein
D004268:DNA-Binding Proteins; D056827:Endosomal Sorting Complexes Required for Transport; D010456:Peptides, Cyclic; D014157:Transcription Factors; D033921:Vesicular Transport Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; D000099177:Tsg101 Protein; C083002:p6 gag protein, Human immunodeficiency virus 1